APA (7th ed.) Citation

M, R., K, T., S, B., C, D., A, P., S, P., . . . M, M. (2017). An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients. Clinica chimica acta; international journal of clinical chemistry, 470, 8. https://doi.org/10.1016/j.cca.2017.04.009

Chicago Style (17th ed.) Citation

M, Rousset, Titier K, Bouchet S, Dutriaux C, Pham-Ledard A, Prey S, Canal-Raffin M, and Molimard M. "An UPLC-MS/MS Method for the Quantification of BRAF Inhibitors (vemurafenib, Dabrafenib) and MEK Inhibitors (cobimetinib, Trametinib, Binimetinib) in Human Plasma. Application to Treated Melanoma Patients." Clinica Chimica Acta; International Journal of Clinical Chemistry 470 (2017): 8. https://doi.org/10.1016/j.cca.2017.04.009.

MLA (9th ed.) Citation

M, Rousset, et al. "An UPLC-MS/MS Method for the Quantification of BRAF Inhibitors (vemurafenib, Dabrafenib) and MEK Inhibitors (cobimetinib, Trametinib, Binimetinib) in Human Plasma. Application to Treated Melanoma Patients." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 470, 2017, p. 8, https://doi.org/10.1016/j.cca.2017.04.009.